Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Purvi Amin

Gastroenterology Orange City, FL Physician Assistant

NPI 1942604798 CMS profile 7450922

2884 Wellness Ave Ste 100, Orange City, FL 32763

Open in the dashboard

General payments

$6,903

349 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Purvi Amin of Orange City, FL is reported in the CMS Open Payments database as having received $6,903 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,579 78
2024 General $1,839 80
2023 General $1,410 82
2022 General $1,492 71
2021 General $583 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Purvi Amin
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Purvi Amin were reported at $1,579. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Purvi Amin Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $583 $352 $106–$1,054 $132
2022 $1,492 $448 $129–$1,270 $149
2023 $1,410 $533 $150–$1,390 $160
2024 $1,839 $605 $160–$1,606 $164
2025 $1,579 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,958 126 payments
  2. Janssen Biotech, Inc. $1,253 59 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $386 23 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $379 22 payments
  5. Pfizer Inc. $309 15 payments
  6. Phathom Pharmaceuticals, Inc. $283 6 payments
  7. Celgene Corporation $260 11 payments
  8. Janssen Scientific Affairs, LLC $235 2 payments
  9. Aimmune Therapeutics, Inc. $203 8 payments
  10. Lilly USA, LLC $197 9 payments
  11. Other $1,440 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,541 342 payments
  2. Education $362 7 payments
Products named General payments · program years 2021–2025
  1. STELARA $1,175 44 payments
  2. RINVOQ $812 38 payments
  3. SKYRIZI Immunology $616 41 payments
  4. TREMFYA $546 26 payments
  5. SIMPONI ARIA $343 23 payments
  6. SIMPONI $343 23 payments
  7. ZENPEP $341 14 payments
  8. ENTYVIO $315 19 payments
  9. XIFAXAN $304 17 payments
  10. SKYRIZI Immunology $292 15 payments
  11. Other $3,582 201 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

360

Median for Physician Assistant: 241

Drug cost

$88,126

Median for Physician Assistant: $4,110

Branded share of claims

29.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 15 $67,781
Linzess Linaclotide Brand 13 $12,339
Mesalamine Generic 11 $2,738
Pantoprazole Sodium Generic 108 $1,274
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 12 $758
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 43 $728
Omeprazole Generic 43 $708
Sucralfate Generic 14 $546
Dicyclomine Hcl Generic 27 $420
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 23 $386

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$21,661

Medicare's payments for the services billed

Medicare patients

171

Average age 73

Services billed

352

92 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 36%
Diabetes 34%
Chronic kidney disease 26%
COPD 20%
Osteoporosis 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $191
  • Janssen Scientific Affairs, LLC $112
$302 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $244
$244 — —
RINVOQ
  • AbbVie, Inc. $125
$125 — —
SKYRIZI
  • AbbVie, Inc. $115
$115 — —
TREMFYA
  • Janssen Biotech, Inc. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record